Financials in USD. Standardized financial statements.
A compact view of how Botanix Pharmaceuticals Limited turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $5.76M | $2.07M | $3.77M | $2.75M | $6.89M | $7.57M | $4.69M | $1.78M | $0 | $0 |
| Revenue Growth? | +178.2% | -45.1% | +36.9% | -60.0% | -9.1% | +61.6% | +163.6% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $3.44M | $3.65M | $3.96M | $10.29M | $6.57M | $102,280 | $1,581 | $11.04M | $3.65M | $0 |
| Gross Profit? | $2.32M | -$1.58M | -$3.05M | -$7.54M | $315,799 | $7.47M | $4.68M | -$9.26M | -$3.65M | $0 |
| Gross Margin? | +40.3% | -76.5% | -80.7% | -273.6% | +4.6% | +98.6% | +100.0% | -521.0% | 0.0% | 0.0% |
| Operating Expenses? | $88.66M | $14.15M | $9.75M | $14.91M | $9.76M | $24.26M | $21.46M | $12.94M | $4.81M | $1.62M |
| Operating Income? | -$86.34M | -$15.46M | -$13.61M | -$22.45M | -$9.45M | -$16.68M | -$17.03M | -$11.01M | -$4.77M | -$1.71M |
| EBITDA? | -$82.16M | -$13.79M | -$8.96M | -$12.99M | -$3.36M | -$16.58M | -$17.16M | $0 | $0 | $0 |
| Income Before Tax | -$86.40M | -$13.87M | -$9.15M | -$13.17M | -$3.33M | -$16.73M | -$17.04M | -$11.01M | -$4.77M | -$1.71M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $4.32M | -$1.63M | -$4.81M | -$428,392 |
| Net Income? | -$86.40M | -$13.87M | -$9.15M | -$13.17M | -$3.33M | -$16.73M | -$17.04M | -$11.01M | -$4.77M | -$1.71M |
| EPS? | $-0.05 | $-0.01 | $-0.01 | $-0.01 | $-0.00 | $-0.02 | $-0.02 | $-0.02 | $-0.01 | $-0.01 |
| Diluted EPS? | $-0.05 | $-0.01 | $-0.01 | $-0.01 | $-0.00 | $-0.02 | $-0.02 | $-0.02 | $-0.01 | $-0.01 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality